Ramucirumab is a medicine used to treat certain types of cancer. It works by blocking a protein called VEGFR2, which helps tumors grow. It's often used in combination with other cancer treatments.
Every report comes from a Lived member, sent anonymously.
Have you tried Cyramza (Ramucirumab) for Colorectal Cancer?
Ramucirumab, sold as Cyramza, is a cancer medicine given by infusion into a vein. It is used for several advanced cancers in adults, usually alongside chemotherapy and usually after earlier treatment has stopped working. For stomach cancer, or cancer where the stomach meets the esophagus (the gastroesophageal junction), it is given alone or with the chemotherapy drug paclitaxel once the cancer has grown during or after first-line chemotherapy. For colorectal cancer that has spread, it is combined with FOLFIRI, a standard three-drug chemotherapy regimen, after earlier treatment including bevacizumab and oxaliplatin. In non-small cell lung cancer that has spread, it has two roles. It can be paired with erlotinib, a daily targeted pill, as a first treatment when the tumor carries certain mutations in the EGFR (epidermal growth factor receptor) gene (exon 19 deletions or the exon 21 L858R mutation). It can also be added to the chemotherapy drug docetaxel after platinum-based chemotherapy has stopped controlling the cancer. For hepatocellular carcinoma, the most common type of liver cancer, it is used alone after treatment with sorafenib, but only when blood levels of alpha-fetoprotein (AFP), a protein many liver tumors release, are 400 ng/mL or higher. Because the approval is limited to that group, the AFP test result decides whether this option is available.
A tumor needs a blood supply to keep growing, so it sends out signals, chiefly a protein called VEGF (vascular endothelial growth factor), that coax nearby blood vessels to sprout new branches. VEGF works by attaching to a receptor on blood vessel cells called VEGFR2. Ramucirumab is a monoclonal antibody, a lab-made protein designed to latch onto one specific target. It binds to VEGFR2 and blocks VEGF from switching it on, which slows the growth of new vessels feeding the tumor. This does not kill cancer cells directly, which is why it is usually combined with chemotherapy or a targeted drug that does. The same effect on blood vessels explains its typical risks, such as higher blood pressure, bleeding and slower wound healing.
Ramucirumab is given in an infusion center or clinic through an IV line. The dose is based on body weight and the cancer being treated. For most uses it is given every two weeks; with docetaxel for lung cancer it is given once every three weeks, on the first day of each chemotherapy cycle. When combined with chemotherapy, ramucirumab is usually given first. The first infusion takes about an hour, and later ones can take about 30 minutes if the first goes smoothly. Before each infusion, the team gives an antihistamine through the IV to lower the chance of a reaction, and adds other premedications if a reaction has happened before. Treatment generally continues for as long as the cancer stays under control and side effects remain manageable, with doses delayed, reduced or stopped when problems arise.
Which side effects are most noticeable depends partly on the chemotherapy or targeted drug given with it. Common ones include tiredness, diarrhea, nosebleeds, mouth sores, reduced appetite, swelling in the legs and rising blood pressure. When combined with chemotherapy, low white blood cell counts are common, which raises infection risk. With erlotinib, hair thinning, protein in the urine and changes in liver blood tests are also frequent. High blood pressure is one of the most consistent effects, so the team checks it at least every two weeks and may start or adjust blood pressure medicine. A severe headache, lightheadedness or a high reading on a home monitor is worth a prompt call to the care team. Infusion reactions usually happen during the first or second infusion. Chills, flushing, back pain, chest tightness or trouble breathing during an infusion should be reported to the nurse straight away. Because the drug affects blood vessels, it raises the risk of bleeding, including from the stomach or bowel. Contact the care team right away for bleeding that is heavy or won't stop, black or bloody stools, vomiting blood or feeling lightheaded. Severe belly pain, repeated vomiting or severe diarrhea also needs a prompt call, since ramucirumab can rarely cause a tear (perforation) in the stomach or intestine. Rarely, it causes clots in arteries that lead to a heart attack or stroke. Call 911 for chest pain or pressure, or for sudden weakness or numbness on one side, a drooping face or trouble speaking. A seizure, sudden loss of vision or new confusion also needs emergency care, as these can signal PRES (posterior reversible encephalopathy syndrome), a rare swelling of the brain that often improves within days once the drug is stopped.
Ramucirumab slows healing, so it has to be planned around surgery. It is normally stopped 28 days before planned surgery and not restarted for at least two weeks after a major operation, and only once the wound has healed. Anyone expecting surgery should make sure both the surgeon and the oncology team know about it. The drug can harm a developing baby. Women who could become pregnant should use effective contraception during treatment and for 3 months after the last dose, and tell the team promptly about a known or suspected pregnancy. Breastfeeding is not advised during treatment and for 2 months afterward. The drug may also reduce fertility in women. Bleeding risk is a particular concern for people with a recent history of coughing up blood, tumors invading major blood vessels or airways, or those taking blood thinners or regular anti-inflammatory pain relievers such as ibuprofen; people in these groups were largely kept out of the main studies, so the risk is less well known. Tell the team about all medicines, including over-the-counter pain relievers and supplements. For people with liver cancer, the degree of underlying cirrhosis (liver scarring) matters. In more advanced cirrhosis, ramucirumab has led to worsening liver function, such as confusion, fluid building up in the abdomen or kidney failure linked to liver disease, so it is used in that setting only when the expected benefit clearly outweighs the risk.
Ramucirumab is not a cure. In clinical trials it added a few months of life on average for people whose cancer had already progressed. In stomach cancer, for example, people receiving it with paclitaxel lived a median of 9.6 months compared with 7.4 months with paclitaxel alone. In EGFR-mutated lung cancer, adding it to erlotinib kept the cancer from growing for longer (a median of about 19 months versus 12), but did not clearly lengthen overall survival. Individual results vary widely, and some people benefit for much longer than the average. Treatment becomes a regular routine of clinic visits every two or three weeks. Each visit usually includes a blood pressure check, and the team regularly tests urine for protein (a sign of kidney strain), along with blood counts and thyroid function. Scans every few months show whether the cancer is responding. If the cancer grows or side effects become too hard to manage, the team will discuss stopping and what other options remain.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Cyramza (Ramucirumab), what you've noticed, or ask the community a question.